FOLH1 and prostate cancer: Examples with clinical relevance include CALAA-01 (PLGA-siRNA) and BIND-014, a docetaxel formulation conjugated with a prostate-specific membrane antigen (PSMA)—targeting ligands used in prostate cancer therapy [22].